港股異動 | 利好疊加 先瑞達醫療盤初一度漲17%創15個月新高
格隆匯12月12日丨先瑞達醫療-B(06669.HK)盤初一度漲超17%,盤中最高報18.48港元創15個月新高價,總市值51.7億港元。公司獲Boston Scientific Group plc溢價約31.6%提部分要約,預期本次部分要約將整合雙方的核心競爭力,並有望創造重大的戰略價值。此前公司獲美國FDA批准Vericor註冊證書。中信建投證券此前表示,作為外周介入領域國產龍頭,看好公司長期發展。短期來看,公司依託外周藥球建立起的先發優勢,可以幫助新獲批產品快速放量。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.